Concepedia

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo, Stephen Johnston, Keun Seok Lee, Eva Ciruelos, Per Eystein Lønning, Wolfgang Janni, Ruth O’Regan, Marie‐Ange Mouret‐Reynier, Dimitar Kalev, Daniel Egle,

The Lancet Oncology · 2017 · 381 citations · 32 references

DOI

Concepts

References

32

Comprehensive molecular portraits of human breast tumours

Nature · 2012 · 12.4K citations · Full text

, , +14

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

José Baselga, Mario Campone, Martine Piccart et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

, , +9

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research · 2006 · 2.6K citations · Full text

, , +16

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · Annals of Oncology · 2016 · 2.1K citations · Full text

, , +11

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology · 2016 · 1.8K citations

, , +17